Four HIV patients who have found resistant to most of the HIV drugs in the city of Vancouver in British Columbia would be given the experimental drugs TMC 114 and TMC 125 as a last hope to save their lives. Though clinical trials with experimental drugs are undertaken under strict protocols this study is tested on a hope to find a cure and save the lives of these four HIV patients.
TMC 125 is Non-nucleoside reverse transcriptase inhibitor, which has found to have high potency of 98% inhibition HIV. The TMC 125 drug was found effective in a study in which patients were found resistant to nevirapine. TMC 114 is a HIV protease inhibitor, which is found to be an analogue to TMC 126 and is found to be effective in reducing HIV virus burden.
These clinical trials are conducted in these four patients who had shown resistance to most of the anti-retroviral drugs. These experimental clinical trials will be conducted after ethical clearance and institutional review clearance.